Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

SIMPLE SUMMARY: Nintedanib is an anti-angiogenic agent that has received approval in the European Union for the treatment of non-small cell lung cancer (NSCLC) after first-line chemotherapy. Here, we explore the possibility that the flavonolignan silibinin—the major bioactive component from the seed...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch-Barrera, Joaquim, Verdura, Sara, Ruffinelli, José Carlos, Carcereny, Enric, Sais, Elia, Cuyàs, Elisabet, Palmero, Ramon, Lopez-Bonet, Eugeni, Hernández-Martínez, Alejandro, Oliveras, Gloria, Buxó, Maria, Izquierdo, Angel, Morán, Teresa, Nadal, Ernest, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394850/
https://www.ncbi.nlm.nih.gov/pubmed/34439322
http://dx.doi.org/10.3390/cancers13164168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394850/
https://www.ncbi.nlm.nih.gov/pubmed/34439322
http://dx.doi.org/10.3390/cancers13164168

Ejemplares similares